miRNA Exosome Agent for Joint Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for joint diseases, such as inflammation and cartilage degeneration, are inadequate in effectively addressing the underlying pathological processes.
Innovation Solution
A novel agent and pharmaceutical composition containing specific miRNAs, including hsa-miR-1199-5p, hsa-miR-1246, hsa-miR-1290, hsa-miR-141-5p, and hsa-miR-4700-5p, derived from exosomes obtained from joint tissue cells, which suppress the expression of inflammatory and cartilage-degrading genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for joint diseases are used, then general symptom management is achieved, but the underlying pathological processes (inflammation and cartilage degeneration) are not effectively addressed
Solution Approach 1:
The patent extracts specific miRNAs (hsa-miR-1199-5p, hsa-miR-1246, hsa-miR-1290, hsa-miR-141-5p, and hsa-miR-4700-5p) from exosomes obtained from joint tissue cells. These extracted miRNAs are then used as active ingredients in the pharmaceutical composition to specifically target and suppress inflammatory and cartilage-degrading genes, thereby addressing the underlying pathological processes rather than just managing symptoms
Solution Approach 2:
The patent uses exosomes as intermediary carriers to deliver the therapeutic miRNAs to target cells. The exosomes, which are naturally occurring membrane-based endoplasmic reticulums, serve as a delivery vehicle that protects the miRNAs and facilitates their uptake by recipient cells, enabling the miRNAs to exert their therapeutic effect on inflammatory and cartilage-degrading genes
2Measurement precision
If exosomes are used as delivery vehicles, then targeted delivery of miRNA is achieved, but the complexity of isolation and purification increases
Solution Approach 1:
The patent employs self-service principles by utilizing the natural properties of exosomes and miRNAs for isolation and purification. The exosomes are isolated based on their natural membrane structure and size (30-100 nm diameter), and the miRNAs are purified based on their specific sequences and characteristics. This approach leverages the inherent properties of the biological materials rather than requiring complex external intervention systems
Solution Approach 2:
The patent utilizes parameter changes in the physical and chemical properties of exosomes and miRNAs to achieve separation and purification. By exploiting differences in size, density, charge, and molecular weight between exosomes and other cellular components, as well as between miRNAs and other RNA molecules, the patent achieves targeted isolation without requiring overly complex purification protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The miRNA-containing agent effectively reduces inflammation and cartilage degeneration by downregulating key inflammatory and cartilage catabolic genes, providing a promising treatment for joint diseases.
Implementation Method 1
the exosome inclusions can be incorporated into a cell on the recipient side, and can perform gene transcription regulation or the like. For example, the microRNA (miRNA) included in the exosome can bind to a target messenger RNA (mnRNA) in the cell on the recipient side to suppress the expression of a target gene
Data Source
AI summary
An object of the present invention is to provide a novel treatment agent and/or preventive agent for a joint disease. The present invention provides an agent for treating and/or preventing a joint disease, containing one or more miRNAs selected from the group consisting of hsa-miR-1199-5p, hsa-miR-1246, hsa-miR-1290, hsa-miR-141-5p, and hsa-miR-4700-5p as an active ingredient. In addition, the present invention provides a pharmaceutical composition for treating and/or preventing a joint disease, containing the agent for treating and/or preventing the joint disease.